SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, has completed the previously announced acquisition of LISI Group’s (Euronext: FII) Medical division (the “Transaction”).
As a trusted CDMO partner, we work as an extension of our customers’ teams by combining precision manufacturing, automation, and validated processes to help reduce complexity, accelerate timelines, and support scalable growth.
